New tool closes gap in harnessing untapped potential of phages

Billy Odell Tucker-Robinson Founder & Host — Banking With Billy Network • Intelligence Network • Data Science • AI Research • World News
Published: 2026-09-25T09:00:27.795Z • Permanent link

Leading researchers at the University of California, Los Angeles, have unveiled a groundbreaking new tool to mutate bacteriophages, a class of viruses that infect bacteria. The innovative technology, developed by Dr. Robert Harrison and his team, has been hailed as a major breakthrough in the field of bacteriophage engineering. By harnessing the power of machine learning algorithms and advanced biotechnology, the UCLA researchers have successfully created a system that can rapidly and accurately design novel bacteriophage genomes.

The tool, dubbed "PhageGenie," uses a combination of machine learning and data analysis to predict the most effective mutations for a given bacteriophage strain. This allows researchers to quickly identify the most promising approaches for harnessing the full potential of these viruses. According to Dr. Harrison, "PhageGenie represents a major leap forward in our understanding of how bacteriophages function and how we can use them to combat bacterial infections." The technology has already generated significant interest among researchers and industry experts, with several prominent companies expressing interest in licensing the technology for potential applications in medicine and agriculture.

Meanwhile, the US National Institutes of Health (NIH) has announced plans to support further research into the use of bacteriophages as a tool for combating antibiotic-resistant bacteria. The NIH has awarded a grant to Dr. Harrison's team to develop a larger-scale version of the PhageGenie system, with the aim of creating a comprehensive platform for designing and testing novel bacteriophage genomes. The grant is seen as a major endorsement of the technology, and is likely to accelerate the development of PhageGenie into a widely-used tool for researchers and industry.

The development of PhageGenie has significant implications for the pharmaceutical and biotechnology industries. Companies such as Intellia Therapeutics and CRISPR Therapeutics are already working on using bacteriophages as a tool for treating genetic diseases. With PhageGenie, these companies will have access to a more powerful and flexible tool for designing and testing novel bacteriophage genomes. This is likely to accelerate the development of new treatments for a range of diseases, from cancer to infectious diseases.

The broader implications of PhageGenie are also significant. The ability to harness the full potential of bacteriophages has the potential to revolutionize the field of microbiology, and could have major impacts on our understanding of the microbial world. For researchers, the tool represents a major breakthrough in the field of bacteriophage engineering, and could open up new avenues for discovery and innovation. For industry, the potential applications of PhageGenie are vast, and could have major impacts on the development of new treatments and therapies.

The development of PhageGenie is part of a larger trend in the field of microbiology. In recent years, there has been a growing recognition of the importance of the microbial world, and the potential for microorganisms to be used as a tool for medicine and agriculture. This trend has been driven in part by advances in biotechnology, which have made it possible to engineer and manipulate microorganisms in ways that were previously impossible. Other researchers, such as Dr. Jennifer Doudna, have also been working on using bacteriophages as a tool for treating genetic diseases.